From operating room to recovery: how Edwards’ SAPIEN 3 Ultra Resilia raises the bar for TAVR

Edwards Lifesciences’ SAPIEN 3 Ultra Resilia transcatheter heart valve combines a low-profile delivery system with treated bovine tissue designed to resist calcification, aiming to extend durability for patients receiving minimally invasive aortic valve replacement.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 1:45 PM ET. Details in the imprint.

With transcatheter aortic valve replacement now standard of care for many patients with severe aortic stenosis, Edwards Lifesciences is leaning on its flagship platform with the SAPIEN 3 Ultra Resilia valve, a system built to make procedures smoother in the cath lab while promising longer-lasting valve tissue inside the heart. The valve pairs a familiar balloon-expandable metal frame with Edwards’ Resilia bovine pericardial tissue, which is treated to reduce calcification and is marketed as offering improved durability compared with earlier generations of surgical bioprostheses, a claim that is increasingly important as TAVR expands to younger, lower-risk patients who may live with the implant for decades. According to the company, SAPIEN 3 Ultra Resilia uses the same Commander delivery system as the rest of the SAPIEN 3 family, so structural heart teams can adopt the new tissue technology without relearning access and deployment techniques.

What SAPIEN 3 Ultra Resilia is designed to do in TAVR

Edwards Lifesciences positions the SAPIEN 3 Ultra Resilia valve as its current high-end transcatheter heart valve for native aortic stenosis, integrating a low-profile, balloon-expandable cobalt-chromium frame with a polyethylene terephthalate (PET) outer skirt to reduce paravalvular leak and improve sealing against the calcified native annulus. The company specifies that the valve is available in multiple diameters, typically ranging from 20 mm to 29 mm, allowing interventional cardiologists to match device size to annular measurements obtained by CT and echocardiography for a broad spectrum of patient anatomy. On its official materials, Edwards emphasizes that the Resilia tissue in this transcatheter valve is processed with a proprietary anti-calcification treatment that blocks free aldehydes, which are known to drive calcific degeneration, with the goal of preserving leaflet flexibility and hemodynamics for longer periods than seen with conventional tissue valves. The official product page describes how the SAPIEN 3 Ultra Resilia heart valve combines the SAPIEN 3 Ultra frame with Resilia tissue to address both procedural performance and long-term durability.

From a workflow standpoint, the SAPIEN 3 Ultra Resilia valve is delivered via transfemoral access using the Commander delivery system, which is designed for controlled flexion and rotation as the device is advanced over a guidewire across the native aortic valve. Interventional teams can rely on radiopaque markers and balloon inflation under fluoroscopy to position the valve precisely, and the system supports rapid pacing during deployment to minimize cardiac motion at the moment of expansion and seating. Because the frame is balloon-expandable rather than self-expanding, operators can better predict the final valve diameter at the annulus once the balloon is inflated to its nominal volume, potentially reducing the risk of device migration in heavily calcified anatomy. Edwards highlights the familiar ergonomics of the handle and shaft for customers already using earlier SAPIEN 3 valves, which means cath labs can incorporate the new valve tissue with minimal additional training, an important consideration for busy centers that schedule multiple TAVR cases per day.

The clinical rationale for Resilia tissue in the transcatheter setting builds on long-term follow-up from surgical valves, such as the INSPIRIS Resilia platform, where data through eight years have shown reduced structural valve deterioration compared with some legacy bioprosthetic comparators. While aortic stenosis patients receiving TAVR in earlier years were often in their 80s or had multiple comorbidities, the risk profile in current practice has shifted to include many patients in their 60s and 70s who may need their valve to remain functional for 15 years or longer to avoid reintervention. Edwards argues that integrating Resilia into a TAVR valve is a logical next step, aiming to bring the same resistance to calcification and tissue degradation into a less invasive procedure that can be done through a small puncture in the groin, typically with next-day discharge in stable cases. A recent overview in the cardiology trade press underscored that this durability focus is central as TAVR volumes rise globally and as device makers compete not only on short-term outcomes such as paravalvular leak but on long-term reintervention rates and hemodynamic performance in younger cohorts. Specialist coverage from TCTMD notes that Resilia-based valves are part of a broader industry shift toward next-generation tissue technologies for long-term TAVR durability.

Regulatory and reimbursement status are also key for US hospitals considering inventory. In the United States, TAVR devices like the SAPIEN 3 Ultra Resilia valve are approved by the Food and Drug Administration for the treatment of symptomatic severe aortic stenosis in patients at various surgical risk categories, following large randomized studies that moved the therapy from inoperable and high-risk patients down to intermediate and low-risk groups. Once approved, transcatheter aortic valve procedures are eligible for Medicare coverage when performed at certified TAVR centers that meet specific volume and quality criteria, and private payers generally align with those policies for appropriately indicated patients. The list price of such valves is substantial and often runs into tens of thousands of dollars per unit, though Edwards does not prominently publish public MSRP figures, and real-world pricing depends on negotiated contracts, procedure bundles, and regional purchasing agreements between hospital systems and the manufacturer.

Outside the US, Edwards Lifesciences markets the SAPIEN 3 Ultra Resilia valve in a range of geographies, subject to local approvals, and often references the system in presentations about the company’s Structural Heart segment. Europe, for example, has been a major market for SAPIEN valves since early CE mark approvals, and physicians there have accumulated extensive experience across different patient profiles and healthcare systems. In Japan and other Asia-Pacific markets, adoption tends to be shaped by national reimbursement decisions, the number of certified TAVR centers, and competition from other manufacturers’ transcatheter valves. Analysts covering the transcatheter heart valve market generally view SAPIEN 3 Ultra Resilia as a premium product within Edwards’ portfolio, complementing earlier SAPIEN generations while anchoring revenue growth in the structural heart franchise as surgeons and interventional cardiologists shift more aortic valve replacement procedures from open surgery to catheter-based approaches. A recent report from Fierce Biotech highlights how Edwards’ structural heart segment, including the SAPIEN line, remains a primary growth driver for the company’s medtech business.

Within Edwards Lifesciences, the SAPIEN 3 Ultra Resilia valve is strategically important because it extends the life of the SAPIEN 3 platform at the high end of the market, targeting centers that want a transcatheter valve with strong procedural performance and a compelling story on tissue longevity for younger patients. Structural heart products, and especially transcatheter aortic valves, account for a significant share of Edwards’ overall revenue and are a central focus of management’s long-term growth planning, as reflected in investor presentations and earnings commentary. Shares of Edwards Lifesciences (US28176E1082) traded on the NYSE at about $85 in recent sessions in mid-June 2026, reflecting investor attention on ongoing TAVR adoption trends and competition in structural heart devices.

SAPIEN 3 Ultra Resilia valve in brief

• Product: SAPIEN 3 Ultra Resilia transcatheter heart valve
• Manufacturer: Edwards Lifesciences Corporation
• Category: Flagship transcatheter aortic valve replacement (TAVR) system
• Launch date: Initially introduced in the early 2020s, with broader availability following subsequent regulatory clearances
• MSRP / Price: Hospital purchase price typically in the tens of thousands of dollars per valve; exact figures vary by contract and region
• Availability: Approved and marketed in the United States and multiple international markets through specialized TAVR centers
• Target audience: Adult patients with severe, symptomatic aortic stenosis who are candidates for transfemoral TAVR as determined by a multidisciplinary heart team
• Key differentiator / USP: Integration of Edwards’ Resilia anti-calcification tissue technology into the proven SAPIEN 3 Ultra frame to combine familiar procedural performance with a focus on long-term durability

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.